Stage III Rectal Cancer: Clinical Trials

5 trials for Stage III Rectal Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 withdrawn. 5 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Withdrawn 1
Phase 25Completed 4, Withdrawn 1

Follow Stage III Rectal Cancer: new trials by email Literature Review of Stage III Rectal Cancer trials Research Report on Stage III Rectal Cancer

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
Capecitabine, 5-FU, Leucovorin - Stage II Rectal Cancer, Stage III Rectal Cancer
Phase 1 / Phase 2WithdrawnUniversity of Texas Southwestern Medical Center2011-03-012020-08-20
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)172007-10-012015-03-31
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)662005-01-012014-06-11
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
oxaliplatin, fluorouracil, external beam radiation therapy - Adenocarcinoma of the Rectum, Stage II Rectal Cancer
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)242000-07-012013-01-16
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
irinotecan hydrochloride, semaxanib, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)682000-03-012013-01-23

Narrower conditions

Rectal Neoplasms (5)  ·  Colonic Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Esthesioneuroblastoma, Olfactory (1)  ·  Pancreatic Neoplasms (1)  ·  Salivary Gland Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Broader conditions

Colorectal Neoplasms (5)  ·  Digestive System Diseases (5)  ·  Digestive System Neoplasms (5)  ·  Gastrointestinal Diseases (5)  ·  Gastrointestinal Neoplasms (5)  ·  Intestinal Diseases (5)  ·  Intestinal Neoplasms (5)  ·  Neoplasms (5)  ·  Neoplasms by Site (5)  ·  Rectal Diseases (5)  ·  Colonic Diseases (3)  ·  Adenocarcinoma (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Bronchogenic (1)

Interventions

Cetuximab (2)  ·  Fluorouracil (2)  ·  Irinotecan (2)  ·  Oxaliplatin (2)  ·  2C4 antibody (1)  ·  Bevacizumab (1)  ·  Capecitabine (1)  ·  Erlotinib Hydrochloride (1)  ·  Gene Expression Profiling (1)  ·  Immunohistochemistry (1)  ·  In Situ Hybridization, Fluorescence (1)  ·  Leucovorin (1)  ·  Polymerase Chain Reaction (1)  ·  Radiation (1)  ·  Semaxinib (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (5)

Top investigators

Alain Mita (1)  ·  David Ryan (1)  ·  James Abbruzzese (1)  ·  Kimmie Ng (1)

NIH funding

N01CM17003 (1), P30CA054174 (1), U01CA062490 (1), U01CA069853 (1), U10CA031946 (1)